These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33217941)

  • 1. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo.
    Maranto C; Udhane V; Jia J; Verma R; Müller-Newen G; LaViolette PS; Pereckas M; Sabharwal L; Terhune S; Pattabiraman N; Njar VCO; Imig JD; Wang L; Nevalainen MT
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33217941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
    Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
    Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.
    Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
    Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
    [No Abstract]   [Full Text] [Related]  

  • 4. STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice.
    Boutillon F; Pigat N; Sala LS; Reyes-Gomez E; Moriggl R; Guidotti JE; Goffin V
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31269779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.
    Talati PG; Gu L; Ellsworth EM; Girondo MA; Trerotola M; Hoang DT; Leiby B; Dagvadorj A; McCue PA; Lallas CD; Trabulsi EJ; Gomella L; Aplin AE; Languino L; Fatatis A; Rui H; Nevalainen MT
    Am J Pathol; 2015 Sep; 185(9):2505-22. PubMed ID: 26362718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT5 and STAT5 Inhibitors in Hematological Malignancies.
    Tolomeo M; Meli M; Grimaudo S
    Anticancer Agents Med Chem; 2019; 19(17):2036-2046. PubMed ID: 31490767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.
    Page BD; Khoury H; Laister RC; Fletcher S; Vellozo M; Manzoli A; Yue P; Turkson J; Minden MD; Gunning PT
    J Med Chem; 2012 Feb; 55(3):1047-55. PubMed ID: 22148584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3',5'-monophosphate and phosphatases.
    Zhang H; Conrad DM; Butler JJ; Zhao C; Blay J; Hoskin DW
    J Immunol; 2004 Jul; 173(2):932-44. PubMed ID: 15240680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.
    Li H; Ahonen TJ; Alanen K; Xie J; LeBaron MJ; Pretlow TG; Ealley EL; Zhang Y; Nurmi M; Singh B; Martikainen PM; Nevalainen MT
    Cancer Res; 2004 Jul; 64(14):4774-82. PubMed ID: 15256446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign.
    Binder C; Lafayette A; Archibeque I; Sun Y; Plewa C; Sinclair A; Emkey R
    Assay Drug Dev Technol; 2008 Feb; 6(1):27-37. PubMed ID: 18336085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
    Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of zebrafish Stat5 expands hematopoietic cell populations in vivo.
    Lewis RS; Stephenson SE; Ward AC
    Exp Hematol; 2006 Feb; 34(2):179-87. PubMed ID: 16459186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.
    Okutani Y; Kitanaka A; Tanaka T; Kamano H; Ohnishi H; Kubota Y; Ishida T; Takahara J
    Oncogene; 2001 Oct; 20(45):6643-50. PubMed ID: 11641791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
    Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
    Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT5 signaling is required for the efficient induction and maintenance of CML in mice.
    Ye D; Wolff N; Li L; Zhang S; Ilaria RL
    Blood; 2006 Jun; 107(12):4917-25. PubMed ID: 16522816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity.
    Park SH; Yamashita H; Rui H; Waxman DJ
    Mol Endocrinol; 2001 Dec; 15(12):2157-71. PubMed ID: 11731617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis.
    Joliot V; Cormier F; Medyouf H; Alcalde H; Ghysdael J
    Oncogene; 2006 Aug; 25(33):4573-84. PubMed ID: 16532027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immunohistochemical approach to monitor the prolactin-induced activation of the JAK2/STAT5 pathway in pancreatic islets of Langerhans.
    Brelje TC; Svensson AM; Stout LE; Bhagroo NV; Sorenson RL
    J Histochem Cytochem; 2002 Mar; 50(3):365-83. PubMed ID: 11850439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin signalling in the mouse hypothalamus is primarily mediated by signal transducer and activator of transcription factor 5b but not 5a.
    Yip SH; Eguchi R; Grattan DR; Bunn SJ
    J Neuroendocrinol; 2012 Dec; 24(12):1484-91. PubMed ID: 22775396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.